Author | Kevin Kavanagh, MD


Eli Lilly Neutralizing Antibodies: Breakthrough for COVID-19 Treatment?

September 18, 2020

Eli Lilly stated LY-CoV555 was “well tolerated” without the observation of any drug-related serious events. And that adverse events were similar to placebo. However, the exact incidence of milder drug reactions which could affect patient acceptance were not given.

Taking Aim at Antibiotic-Resistant Bacteria During COVID

September 16, 2020

Patients afflicted with COVID-19 have an increased susceptibility to antibiotic resistant infections both from prolonged hospitalizations and the use of immunocompromising agents such as dexamethasone.

Viewpoint: Infection Preventionist Guide to Dealing with COVID Misinformation

September 08, 2020

It is imperative that infection preventionists engage and combat this messaging on social media and wherever it occurs. To not do so, allows misinformation to fan the pandemic, placing all of our lives at risk.

Is COVID-19 Primarily a Heart and Vascular Disease?

September 08, 2020

Infection preventionists need to be able to articulate to those who feel that the young are safe just because their fatality rate is extremely low, that even in this age group there are major concerns regarding long-term consequences of this virus.